Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer

Francesco Saverio Mennini, Andrea Marcellusi, Gianluca Fabiano, Lorenza Rimassa, Armando Santoro, Nicola Personeni

Research output: Contribution to journalArticle


Aim: Cetuximab is used for the treatment of RAS wild-type metastatic colorectal cancer patients. Standard administration schedule is once a week; however, the bioequivalence of an every-other-week (EOW) schedule was demonstrated. Methods: We compared a base case scenario of 100% weekly administration to an EOW at 50 or 100%. Medical examinations, patient management and loss of productivity were considered. Results: Base case was estimated at €100.6 million versus €92.8 million and €84.9 million of EOW 50 and 100%, which showed a cost reduction of 8 and 16%, respectively. Indirect costs accounted for 65% in both scenarios. Conclusion: The adoption of an EOW administration schedule of cetuximab reduced direct and indirect costs substantially.

Original languageEnglish
Pages (from-to)2107-2112
Number of pages6
JournalFuture oncology (London, England)
Issue number18
Publication statusPublished - Jun 2019



  • Antineoplastic Agents, Immunological/administration & dosage
  • Cetuximab/administration & dosage
  • Colorectal Neoplasms/diagnosis
  • Drug Administration Schedule
  • Female
  • Health Care Costs
  • Health Expenditures
  • Humans
  • Incidence
  • Male
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Population Surveillance

Cite this